Skip to main content

Advertisement

Articles

Page 2 of 2

  1. In Ethiopia, cervical cancer (CC) ranks the 2nd most frequent cancer and the country had 27.19 million women at risk of developing the disease though only 0.6 % women age 18-69 years was screened every 3 years...

    Authors: Netsanet Belete, Yosief Tsige and Habtamu Mellie

    Citation: Gynecologic Oncology Research and Practice 2015 2:6

    Content type: Research

    Published on:

  2. Recently accumulated evidence has strongly indicated that the fallopian tube is the site of origin for the majority of high-grade serous ovarian or peritoneal carcinomas. As a result, recommendations have been...

    Authors: Gillian E. Hanley, Jessica N. McAlpine, Janice S. Kwon and Gillian Mitchell

    Citation: Gynecologic Oncology Research and Practice 2015 2:5

    Content type: Review

    Published on:

  3. Compared to other subtypes of epithelial ovarian cancer, clear cell carcinoma of the ovary bears an ominous reputation for chemotherapy resistance, increased relapse rate, and diminished survival. Among patien...

    Authors: Michael P. Castro, Bradford P. Whitcomb, Deborah A. Zajchowski and Robert L. Coleman

    Citation: Gynecologic Oncology Research and Practice 2015 2:4

    Content type: Case report

    Published on:

  4. Cancer of uterine cervix is the second most common cause of cancer related deaths among women. The aim of this study is to report the experience of Military Hospital Mohamed V in the management of cervical can...

    Authors: Mohammed Elmarjany, Abdelhak Maghous, Rachid Razine, Elamin Marnouche, Khalid Andaloussi, Amine Bazine, Issam Lalya, Noha Zaghba, Khalid Hadadi, Hassan Sifat, Baba Habib, Jaouad Kouach and Hamid Mansouri

    Citation: Gynecologic Oncology Research and Practice 2015 2:2

    Content type: Research

    Published on:

  5. Clear cell adenocarcinoma of the cervix is a rare tumor of the lower genital tract. It has been described in young women with a history of intra uterine exposure to diethylstilbestrol. This tumor is characteri...

    Authors: Ablavi Adani-Ifè, Emma Goldschmidt, Pasquale Innominato, Ayhan Ulusakarya, Hassan Errihani, Philippe Bertheau and Jean François Morère

    Citation: Gynecologic Oncology Research and Practice 2015 2:3

    Content type: Case report

    Published on:

  6. Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate origins, pathogenesis, clinical features, and outcomes. Additionally, previous classificati...

    Authors: Lauren Patterson Cobb, Stephanie Gaillard, Yihong Wang, Ie-Ming Shih and Angeles Alvarez Secord

    Citation: Gynecologic Oncology Research and Practice 2015 2:1

    Content type: Review

    Published on:

  7. Pelvic actinomycosis comprises a rare, subacute to chronic bacterial infection characterised by suppurative and granulomatous inflammation. Diagnosis is difficult as it may simulate pelvic malignancies. Labora...

    Authors: Alex Laios, Iryna Terekh, Hooman Soleymani Majd, Pubudu Pathiraja, Sanjiv Manek and Krishnayan Haldar

    Citation: Gynecologic Oncology Research and Practice 2014 1:5

    Content type: Case report

    Published on:

  8. While most gynecologic cancers respond to first-line cytotoxic chemotherapy, treatment of recurrent disease is frequently associated with acquired drug resistance. In order to find an in vitro surrogate of thi...

    Authors: Heather J Dalton, James Fiorica, Candace K McClure, Rodney P Rocconi, Fernando O Recio, John L Levocchio, Matthew O Burrell and Bradley J Monk

    Citation: Gynecologic Oncology Research and Practice 2014 1:7

    Content type: Research

    Published on:

  9. Metastatic carcinoma to the uterine cervix from colorectal cancer, through haematogenous or lymphatic spread, is extremely rare. We report the case of a 59 year old woman in whom cervical metastasis was diagno...

    Authors: Soufiane Berhili, Basma El Khannoussi, Selma Kadiri, Imane Mezouri, Amine Bazine, Asmae Touil, Imane El Khiyat, Tayeb Kebdani and Noureddine Benjaafar

    Citation: Gynecologic Oncology Research and Practice 2014 1:6

    Content type: Case report

    Published on:

  10. Drug discovery in the ovarian cancer arena continues to launch important new clinical trials. Many biologic agents are being studied in phase II and phase III clinical trials for recurrent disease. These agent...

    Authors: Steven J Gibson, Krishnansu S Tewari, Bradley J Monk and Dana M Chase

    Citation: Gynecologic Oncology Research and Practice 2014 1:3

    Content type: Review

    Published on:

  11. To explore the activity of dasatinib alone and in combination with gemcitabine and docetaxel in uterine leiomyosarcoma (uLMS) cell lines, and determine if dasatinib inhibits the SRC pathway.

    Authors: Micael Lopez-Acevedo, Lisa Grace, Deanna Teoh, Regina Whitaker, David J Adams, Jingquan Jia, Andrew B Nixon and Angeles Alvarez Secord

    Citation: Gynecologic Oncology Research and Practice 2014 1:2

    Content type: Research

    Published on:

Advertisement